Ascendis First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort Phase 1/2

 

• Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β/γ in combination with chemotherapy
• Initial data suggest clinical activity in heavily pre-treated PROC patients and that TransCon IL-2 β/γ in combination with chemotherapy was generally well-tolerated

https://www.globenewswire.com/news-release/2024/09/13/2945939/0/en/Ascendis-to-Present-First-Results-from-Platinum-Resistant-Ovarian-Cancer-PROC-Cohort-of-the-Phase-1-2-IL-Believe-Trial-at-ESMO-2024.html